Decision analysis of dutasteride use for patients with negative prostate biopsy Academic Article uri icon

Overview

MeSH Major

  • 5-alpha Reductase Inhibitors
  • Azasteroids
  • Prostatic Neoplasms

abstract

  • Clinicians who are willing to treat at least 23 patients with dutasteride for 2 years to avoid 1 prostate cancer diagnosis should offer dutasteride after initial negative biopsy. Clinicians not willing to do so might consider dutasteride for its additional benefit of reducing unnecessary biopsy, although this benefit is apparent only under very restrictive conditions. It is difficult to justify extending treatment with dutasteride for >2 years.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4308688

Digital Object Identifier (DOI)

  • 10.1016/j.urology.2014.08.048

PubMed ID

  • 25623680

Additional Document Info

start page

  • 337

end page

  • 41

volume

  • 85

number

  • 2